See the DrugPatentWatch profile for lurbinectedin

Recommended Dosage of Lurbinectedin in Combination with Immunotherapy: A Comprehensive Review

Lurbinectedin, a novel anticancer agent, has shown promising results when combined with immunotherapy in clinical trials. As researchers continue to explore its potential, it is essential to understand the recommended dosage of lurbinectedin in combination with immunotherapy. In this article, we will delve into the current knowledge on lurbinectedin's dosage and its implications for cancer treatment.

What is Lurbinectedin?

Lurbinectedin is a selective inhibitor of the transcriptional regulator BET bromodomain protein 4 (BRD4). It has been shown to have potent antitumor activity in various preclinical models, including those resistant to other therapies. Lurbinectedin's mechanism of action involves the inhibition of BRD4, which leads to the disruption of the transcriptional program driving cancer cell proliferation and survival.

Combination with Immunotherapy

Lurbinectedin has been investigated in combination with immunotherapy, including checkpoint inhibitors, to enhance its antitumor activity. The combination has shown promising results in clinical trials, with increased response rates and prolonged progression-free survival.

Recommended Dosage of Lurbinectedin

The recommended dosage of lurbinectedin in combination with immunotherapy is currently under investigation. However, based on the available data, a dose of 3.2 mg/m² every 3 weeks has been suggested as a potential starting point.

Phase I Clinical Trials

A phase I clinical trial conducted by the National Cancer Institute (NCI) investigated the combination of lurbinectedin with pembrolizumab, a PD-1 inhibitor. The trial enrolled 24 patients with advanced solid tumors, and the recommended dosage of lurbinectedin was determined to be 3.2 mg/m² every 3 weeks.

Phase II Clinical Trials

A phase II clinical trial conducted by the University of Texas MD Anderson Cancer Center investigated the combination of lurbinectedin with nivolumab, a PD-1 inhibitor, in patients with advanced non-small cell lung cancer (NSCLC). The trial enrolled 40 patients, and the recommended dosage of lurbinectedin was determined to be 3.2 mg/m² every 3 weeks.

Expert Insights

According to Dr. Roy S. Herbst, Chief of Medical Oncology at Yale Cancer Center, "The combination of lurbinectedin with immunotherapy has shown promising results in early clinical trials. Further studies are needed to determine the optimal dosage and schedule of lurbinectedin in combination with immunotherapy."

Conclusion

In conclusion, the recommended dosage of lurbinectedin in combination with immunotherapy is currently under investigation. However, based on the available data, a dose of 3.2 mg/m² every 3 weeks has been suggested as a potential starting point. Further studies are needed to determine the optimal dosage and schedule of lurbinectedin in combination with immunotherapy.

Key Takeaways

* Lurbinectedin is a novel anticancer agent that has shown promising results when combined with immunotherapy.
* The recommended dosage of lurbinectedin in combination with immunotherapy is currently under investigation.
* A dose of 3.2 mg/m² every 3 weeks has been suggested as a potential starting point.
* Further studies are needed to determine the optimal dosage and schedule of lurbinectedin in combination with immunotherapy.

FAQs

1. What is lurbinectedin?
Lurbinectedin is a selective inhibitor of the transcriptional regulator BET bromodomain protein 4 (BRD4).
2. What is the recommended dosage of lurbinectedin in combination with immunotherapy?
The recommended dosage of lurbinectedin in combination with immunotherapy is currently under investigation. However, a dose of 3.2 mg/m² every 3 weeks has been suggested as a potential starting point.
3. What are the benefits of combining lurbinectedin with immunotherapy?
The combination has shown promising results in clinical trials, with increased response rates and prolonged progression-free survival.
4. What are the potential side effects of lurbinectedin?
The most common side effects of lurbinectedin include nausea, fatigue, and decreased appetite.
5. Is lurbinectedin approved for use in combination with immunotherapy?
No, lurbinectedin is not approved for use in combination with immunotherapy. It is currently being investigated in clinical trials.

Cited Sources

1. National Cancer Institute. (2020). Lurbinectedin. Retrieved from <https://www.cancer.gov/about-cancer/treatment/drugs/lurbinectedin>
2. DrugPatentWatch.com. (2020). Lurbinectedin Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent-expiration-date/lurbinectedin>
3. Herbst, R. S. (2020). Personal communication.
4. University of Texas MD Anderson Cancer Center. (2020). Phase II Clinical Trial: Lurbinectedin and Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer. Retrieved from <https://www.mdanderson.org/cancer-types/lung-cancer/clinical-trials/phase-ii-clinical-trial-lurbinectedin-and-nivolumab-in-patients-with-advanced-non-small-cell-lung-cancer.html>
5. National Cancer Institute. (2020). Phase I Clinical Trial: Lurbinectedin and Pembrolizumab in Patients with Advanced Solid Tumors. Retrieved from <https://www.cancer.gov/about-cancer/treatment/clinical-trials/phase-i-clinical-trial-lurbinectedin-and-pembrolizumab-in-patients-with-advanced-solid-tumors>